These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8884168)

  • 1. Metabolite profiles in patients on high-dose valproate monotherapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsy Res; 1996 Oct; 25(2):107-12. PubMed ID: 8884168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproate metabolites and hepatotoxicity in an epileptic population.
    Tennison MB; Miles MV; Pollack GM; Thorn MD; Dupuis RE
    Epilepsia; 1988; 29(5):543-7. PubMed ID: 3137018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal metabolism of valproic acid in fatal hepatic failure.
    Kochen W; Schneider A; Ritz A
    Eur J Pediatr; 1983 Oct; 141(1):30-5. PubMed ID: 6416845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion of valproate and some metabolites in chronically treated patients.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Ther Drug Monit; 1989; 11(2):127-33. PubMed ID: 2497561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
    Murakami K; Sugimoto T; Nishida N; Kobayashi Y; Kuhara T; Matsumoto I
    Brain Dev; 1992 May; 14(3):178-81. PubMed ID: 1514659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study.
    Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T
    Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
    Löscher W; Wahnschaffe U; Hönack D; Drews E; Nau H
    Epilepsy Res; 1993 Dec; 16(3):183-94. PubMed ID: 8119269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid overdose and L-carnitine therapy.
    Ishikura H; Matsuo N; Matsubara M; Ishihara T; Takeyama N; Tanaka T
    J Anal Toxicol; 1996; 20(1):55-8. PubMed ID: 8837953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
    Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
    Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal liver failure in 16 children with valproate therapy.
    Scheffner D; König S; Rauterberg-Ruland I; Kochen W; Hofmann WJ; Unkelbach S
    Epilepsia; 1988; 29(5):530-42. PubMed ID: 3137017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children versus adults: pharmacokinetic and adverse-effect differences.
    Anderson GD
    Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA.
    Gopaul S; Farrell K; Abbott F
    Epilepsia; 2003 Mar; 44(3):322-8. PubMed ID: 12614387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.